Arcutis to Present at the Wedbush PacGrow Healthcare Conference
Arcutis Biotherapeutics (Nasdaq: ARQT) will participate in the Wedbush PacGrow Healthcare Conference on August 12, 2020, at 10:10 a.m. PT / 1:10 p.m. ET. The presentation will be available via webcast on Arcutis' website, with an archived replay accessible for 30 days post-conference. Arcutis focuses on developing treatments for immune-mediated dermatological diseases, using advancements in immunology to tackle significant challenges. Their lead candidate, topical roflumilast, aims to improve care for conditions like plaque psoriasis and atopic dermatitis.
- None.
- None.
WESTLAKE VILLAGE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Arcutis management will participate in a presentation during the Wedbush PacGrow Healthcare Conference Webcast taking place August 11 - 12, 2020.
Details for the presentation are as follows:
Wedbush PacGrow Healthcare Conference
Presentation Date: Wednesday, August 12, 2020
Presentation Time: 10:10 a.m. PT / 1:10 p.m. ET
The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at https://investors.arcutis.com/events-and-presentations. Arcutis will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Arcutis - Bioscience, applied to the skin.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.
Investors and Media:
Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
harmstrong@arcutis.com
805-418-5006, Ext. 740
FAQ
When will Arcutis Biotherapeutics present at the Wedbush PacGrow Healthcare Conference?
How can I access the Arcutis Biotherapeutics conference presentation?
What is the focus of Arcutis Biotherapeutics?
What is the lead product candidate of Arcutis Biotherapeutics?
